DOACs also beneficial for elderly AF and VTE patients

11-10-2016 • Sadlon AH, Swiss Med Wkly, 2016
Rivaroxaban, apixaban, dabigatran and edoxaban were superior to VKAs in a meta-analysis of 8 studies comprising elderly patients with atrial fibrillation or venous thromboembolism. Read more

Recurrent risk varies substantially in vascular patients: risk stratification can be improved

10-10-2016 • Kaasenbrood L, et al., Circulation 2016
There is substantial variation in the estimated 10-year risk of recurrent vascular events in patients with vascular disease that supports the need for optimisation of risk stratification of these patients. Read more

Patients at very high CV risk would benefit from stricter monitoring and adherence to guidelines

26-9-2016 • Heintjes E, et al., Curr res med opin 2016
Despite lipid-lowering therapy, a large proportion of patients with CV events and/or T2DM did not meet the less stringent Dutch LDL-c target (2.5 mmol/L), BP and HbA1c targets.
  Read more

Metabolic factors may identify individuals prone to develop statin-related diabetes

19-9-2016 • Kohli P et al., Am J Cardiol 2016
The diabetogenic impact of statin treatment is relatively modest, but is aggravated if plasma glucose, TG concentrations and BMI increase. Read more

Very low BP in CAD patients associated with increased CV morbidity and mortality

12-9-2016 • Vidal-Petiot E et al., Lancet 2016
In the large observational CLARIFY cohort of patients with hypertension and CAD, SBP< 120 mmHg and DBP<70 mmHg were associated with increased CV outcomes, even after multiple adjustments. Read more
News • 6-9-2016

EPCCS consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care

General practitioners representing various European countries discussed recent developments in the SPAF field, and specific implications for primary care in an expert meeting. This meeting resulted in a practical guidance for European GPs. Read more

Lower mortality rate with 25 years of intensive lipid-lowering therapy of CAD

10-10-2016 • Zhao XQ et al., J Clin Lipidol 2016
Intensive lipid-lowering therapy for 25 years was associated with significant reductions in CV and total mortality in men with increased LDL-C levels and established coronary artery disease. Read more
News • 28-9-2016

Better sleep for better cardiometabolic health

AHA issued a Scientific Statement in which they review evidence on the relation between too short and too long sleep duration and CV risk, and call for more awareness in clinical practice. Read more

CV incidence decreased with tea consumption

26-9-2016 • Miller PE, et al, Am J Med, 2016
Both prevalence and progression of coronary artery calcium and number of CV events were decreased when drinking more than one cup of tea a day.  Read more

Established risk factors cannot explain gender differences in MI risk

15-9-2016 • Albrektsen G et al., JAMA Intern Med 2016
Compared with women, men have approximately twice the risk of MI. This difference cannot be explained by established CHD risk factors, it persists throughout life but declines with age. Read more
News • 7-9-2016

Important debate about interpretation of SPRINT-data at ESC congress

ESC 2016 During a debate, SPRINT received substantial critique, with implications for the interpretation of the results and for the question whether these should influence new guidelines. Read more
News • 5-9-2016

Study on long term exposure to low LDL-c and low SBP suggests that most CV events are preventable

ESC 2016 Exposure to low levels of LDL-c and SBP have independent, multiplicative and cumulative causal effects on CV risk, according to a Mendelian randomisation study. Read more

Upcoming meetings

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...